Cargando…

Moderate to Severe Soft Tissue Diabetic Foot Infections: A Randomized, Controlled, Pilot Trial of Post-debridement Antibiotic Treatment for 10 versus 20 days

BACKGROUND: The optimal duration of antibiotic therapy for soft-tissue infections of the diabetic foot remains unknown. OBJECTIVE: We determine if antibiotic therapy after debridement for a short (10 days), compared with a long (20 days), duration for soft-tissue infections of the diabetic foot resu...

Descripción completa

Detalles Bibliográficos
Autores principales: Truong-Thanh, Gariani, Karim, Richard, Jean-Christophe, Kressmann, Benjamin, Jornayvaz, François R., Philippe, Jacques, Lipsky, Benjamin A., Uçkay, Ilker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259031/
https://www.ncbi.nlm.nih.gov/pubmed/35623048
http://dx.doi.org/10.1097/SLA.0000000000005205
_version_ 1784741682632196096
author Truong-Thanh,
Gariani, Karim
Richard, Jean-Christophe
Kressmann, Benjamin
Jornayvaz, François R.
Philippe, Jacques
Lipsky, Benjamin A.
Uçkay, Ilker
author_facet Truong-Thanh,
Gariani, Karim
Richard, Jean-Christophe
Kressmann, Benjamin
Jornayvaz, François R.
Philippe, Jacques
Lipsky, Benjamin A.
Uçkay, Ilker
author_sort Truong-Thanh,
collection PubMed
description BACKGROUND: The optimal duration of antibiotic therapy for soft-tissue infections of the diabetic foot remains unknown. OBJECTIVE: We determine if antibiotic therapy after debridement for a short (10 days), compared with a long (20 days), duration for soft-tissue infections of the diabetic foot results in similar rates of clinical remission and adverse events (AE). SUMMARY OF BACKGROUND DATA: The optimal duration of systemic antibiotic therapy, after successful debridement, for soft tissue infections of diabetic patients is unknown. Because of the high recurrence risk, overuse is commonplace. METHODS: This was a randomized, controlled, non-inferiority pilot trial of cases of diabetic foot infection (excluding osteomyelitis) with the primary outcome of “clinical remission at 2-months follow-up”. RESULTS: Among 66 enrolled episodes (17% females; median age 71 years), we randomized 35 to the 10-day arm and 31 to the 20-day arm. The median duration of the parenteral antibiotic therapy was 1 day, with the remainder given orally. In the intention-to-treat population, we achieved clinical remission in 27 (77%) patients in the 10-day arm compared to 22 (71%) in the 20-days arm (P = 0.57). There were a similar proportion in each arm of AE (14/35 versus 11/31; P = 0.71), and remission in the per-protocol population (25/32 vs 18/27; P = 0.32). Overall, 8 soft tissue DFIs in the 10-day arm and 5 cases in the 20-day arm recurred as a new osteomyelitis [8/35 (23%) versus 5/31 (16%); P = 0.53]. Overall, the number of recurrences limited to the soft tissues was 4 (6%). By multivariate analysis, rates of remission (intention-to-treat population, hazard ratio 0.6, 95%CI 0.3-1.1; per-protocol population 0.8, 95%CI 0.4-1.5) and AE were not significantly different with a 10-day compared to 20-day course. CONCLUSIONS: In this randomized, controlled pilot trial, post-debridement antibiotic therapy for soft tissue DFI for 10 days gave similar (and non-inferior) rates of remission and AEs to 20 days. A larger confirmatory trial is under way. TRIAL REGISTRATION: ClinicalTrials NCT03615807.
format Online
Article
Text
id pubmed-9259031
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-92590312022-07-08 Moderate to Severe Soft Tissue Diabetic Foot Infections: A Randomized, Controlled, Pilot Trial of Post-debridement Antibiotic Treatment for 10 versus 20 days Truong-Thanh, Gariani, Karim Richard, Jean-Christophe Kressmann, Benjamin Jornayvaz, François R. Philippe, Jacques Lipsky, Benjamin A. Uçkay, Ilker Ann Surg Randomized Controlled Trials BACKGROUND: The optimal duration of antibiotic therapy for soft-tissue infections of the diabetic foot remains unknown. OBJECTIVE: We determine if antibiotic therapy after debridement for a short (10 days), compared with a long (20 days), duration for soft-tissue infections of the diabetic foot results in similar rates of clinical remission and adverse events (AE). SUMMARY OF BACKGROUND DATA: The optimal duration of systemic antibiotic therapy, after successful debridement, for soft tissue infections of diabetic patients is unknown. Because of the high recurrence risk, overuse is commonplace. METHODS: This was a randomized, controlled, non-inferiority pilot trial of cases of diabetic foot infection (excluding osteomyelitis) with the primary outcome of “clinical remission at 2-months follow-up”. RESULTS: Among 66 enrolled episodes (17% females; median age 71 years), we randomized 35 to the 10-day arm and 31 to the 20-day arm. The median duration of the parenteral antibiotic therapy was 1 day, with the remainder given orally. In the intention-to-treat population, we achieved clinical remission in 27 (77%) patients in the 10-day arm compared to 22 (71%) in the 20-days arm (P = 0.57). There were a similar proportion in each arm of AE (14/35 versus 11/31; P = 0.71), and remission in the per-protocol population (25/32 vs 18/27; P = 0.32). Overall, 8 soft tissue DFIs in the 10-day arm and 5 cases in the 20-day arm recurred as a new osteomyelitis [8/35 (23%) versus 5/31 (16%); P = 0.53]. Overall, the number of recurrences limited to the soft tissues was 4 (6%). By multivariate analysis, rates of remission (intention-to-treat population, hazard ratio 0.6, 95%CI 0.3-1.1; per-protocol population 0.8, 95%CI 0.4-1.5) and AE were not significantly different with a 10-day compared to 20-day course. CONCLUSIONS: In this randomized, controlled pilot trial, post-debridement antibiotic therapy for soft tissue DFI for 10 days gave similar (and non-inferior) rates of remission and AEs to 20 days. A larger confirmatory trial is under way. TRIAL REGISTRATION: ClinicalTrials NCT03615807. Lippincott Williams & Wilkins 2022-08 2021-09-15 /pmc/articles/PMC9259031/ /pubmed/35623048 http://dx.doi.org/10.1097/SLA.0000000000005205 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Randomized Controlled Trials
Truong-Thanh,
Gariani, Karim
Richard, Jean-Christophe
Kressmann, Benjamin
Jornayvaz, François R.
Philippe, Jacques
Lipsky, Benjamin A.
Uçkay, Ilker
Moderate to Severe Soft Tissue Diabetic Foot Infections: A Randomized, Controlled, Pilot Trial of Post-debridement Antibiotic Treatment for 10 versus 20 days
title Moderate to Severe Soft Tissue Diabetic Foot Infections: A Randomized, Controlled, Pilot Trial of Post-debridement Antibiotic Treatment for 10 versus 20 days
title_full Moderate to Severe Soft Tissue Diabetic Foot Infections: A Randomized, Controlled, Pilot Trial of Post-debridement Antibiotic Treatment for 10 versus 20 days
title_fullStr Moderate to Severe Soft Tissue Diabetic Foot Infections: A Randomized, Controlled, Pilot Trial of Post-debridement Antibiotic Treatment for 10 versus 20 days
title_full_unstemmed Moderate to Severe Soft Tissue Diabetic Foot Infections: A Randomized, Controlled, Pilot Trial of Post-debridement Antibiotic Treatment for 10 versus 20 days
title_short Moderate to Severe Soft Tissue Diabetic Foot Infections: A Randomized, Controlled, Pilot Trial of Post-debridement Antibiotic Treatment for 10 versus 20 days
title_sort moderate to severe soft tissue diabetic foot infections: a randomized, controlled, pilot trial of post-debridement antibiotic treatment for 10 versus 20 days
topic Randomized Controlled Trials
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259031/
https://www.ncbi.nlm.nih.gov/pubmed/35623048
http://dx.doi.org/10.1097/SLA.0000000000005205
work_keys_str_mv AT truongthanh moderatetoseveresofttissuediabeticfootinfectionsarandomizedcontrolledpilottrialofpostdebridementantibiotictreatmentfor10versus20days
AT garianikarim moderatetoseveresofttissuediabeticfootinfectionsarandomizedcontrolledpilottrialofpostdebridementantibiotictreatmentfor10versus20days
AT richardjeanchristophe moderatetoseveresofttissuediabeticfootinfectionsarandomizedcontrolledpilottrialofpostdebridementantibiotictreatmentfor10versus20days
AT kressmannbenjamin moderatetoseveresofttissuediabeticfootinfectionsarandomizedcontrolledpilottrialofpostdebridementantibiotictreatmentfor10versus20days
AT jornayvazfrancoisr moderatetoseveresofttissuediabeticfootinfectionsarandomizedcontrolledpilottrialofpostdebridementantibiotictreatmentfor10versus20days
AT philippejacques moderatetoseveresofttissuediabeticfootinfectionsarandomizedcontrolledpilottrialofpostdebridementantibiotictreatmentfor10versus20days
AT lipskybenjamina moderatetoseveresofttissuediabeticfootinfectionsarandomizedcontrolledpilottrialofpostdebridementantibiotictreatmentfor10versus20days
AT uckayilker moderatetoseveresofttissuediabeticfootinfectionsarandomizedcontrolledpilottrialofpostdebridementantibiotictreatmentfor10versus20days